Imaging

• eyeo, startup di computer vision con sede nei Paesi Bassi, ha ottenuto 40 milioni di euro in finanziamenti Series A guidati da Innovation Industries, portando il totale dei finanziamenti a 55 milioni di euro. • Il round ha visto la partecipazione degli investitori esistenti imec.xpand, Invest-NL Deep Tech Fund, QBIC fund, High-Tech Gründerfonds e Brabant Development Agency. • I fondi sosterranno il primo team interno di eyeo per la progettazione di chip nanofotonici in grado di dividere la luce invece di filtrarla, recuperando così il 70% della luce attualmente scartata dai sensori d'immagine.

• Indian innovators unveiled a breakthrough drone imaging technology on May 3, 2026, that completely eliminates the need for germanium, a critical mineral prone to supply chain disruptions from China. • The new system uses alternative materials to maintain high-resolution infrared imaging capabilities, enabling drones for defense, agriculture, and surveillance without vulnerabilities. • This development enhances India's strategic autonomy in drone tech amid global chip shortages and export restrictions, reducing dependency on imported rare earths.

• MIT researchers discovered that chaotic laser light can self-organize into a highly focused 'pencil beam' under precise conditions, enabling rapid 3D imaging of the blood-brain barrier. • The new method images at speeds 25 times faster than current techniques and tracks drug movement into brain cells in real time. • This breakthrough could accelerate treatments for neurological diseases by allowing high-precision observation of protein absorption in cells.

• Telix Pharmaceuticals resubmitted its New Drug Application to the U.S. FDA on March 16, 2026, for TLX101-Px (Pixclara®), a PET imaging agent targeting gliomas in adults and pediatrics. • The agent received Orphan Drug and Fast Track designations from the FDA due to its potential to address unmet needs in post-treatment glioma management, with 18F-FET PET already in international guidelines but no U.S.-approved equivalent. • Glioblastoma multiforme (GBM), the most common aggressive primary brain cancer, affects about 22,000 new U.S. cases yearly, with recurrence nearly universal and median survival of 12-15 months post-diagnosis.